Over the past decades, PARP1 came into focus as a target in clinical oncology, since PARP inhibitors were identified to act as chemosensitizers in combination with classical DNA-damaging therapies or as monotherapeutic agents to treat cancers with defects in HR repair according to the concept of synthetic lethality. The gene discussed is PARP1; the disease is cancer.